indications for glp-1 agonists The science on receptor has outpaced the public narrative. While headlines chase the latest prescription numbers, evidence-based practice demands we hold the line: obesity is a chronic, relapsing condition; not GLP-1 receptor agonists are transforming
Description
Slowly increasing the dose of a GLP-1 medication allows the body time to adjust to the changes that are occurring, especially the slowing of gastric motility, says Currier, So the key to avoiding the nausea as much as possible is to take the titration phase slowly and allow the body time to acclimate appropriately. If someone increases the dose too quickly or overdoses, theyre more likely to experience severe nausea
Menopause also accelerates the natural loss of muscle mass, a condition known as sarcopenia, and reduces your total daily energy expenditure, making it even harder to maintain a healthy weight or lose excess fat

These dual RAs are being evaluated mainly in T2D, T1D, overweight/obesity, and few other possible indications (Figure 2)
Restaurants will need to understand how GLP-1RAs may impact their future demand and what changes they need to make to their menu options, pricing and packaging and customer experience
1 Consider continuing metformin without dose reductions

Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression
